Regorafenib plus avelumab in advanced neuroendocrine tumors — and the IDO1 biomarker that predicts resistance
Why do gastric cancers resist PD-1 plus antiangiogenesis? Spatial and plasma profiling points to M2 macrophages
Which biliary tract cancers benefit from regorafenib–avelumab — and which biomarkers matter?
Can CD163 macrophages help select MSS colorectal cancer patients for regorafenib plus avelumab?
